Overview
- Samsung invested $175 million in an expanded Series E round and now holds the largest single ownership stake in San Diego‑based Element Biosciences.
- The move follows Samsung’s earlier participation in Element’s Series D and represents a deeper shift by the company into healthcare beyond its consumer electronics and semiconductor businesses.
- Element develops next‑generation DNA sequencing systems, including the Aviti 24, and is preparing higher‑throughput and diagnostic platforms called Vitari and Aviti Dx that the company says aim to cut testing costs.
- Multiomics combines DNA, RNA and protein data to give richer biological insight than DNA alone, and Samsung says it will combine that capability with its artificial intelligence and medical‑device expertise to help build personalized diagnostics.
- Commercial use of sequencing‑based diagnostics will still need further clinical validation and regulatory approval, but the deal could speed product development, lower analysis costs, and expand access to precision oncology and other targeted tests.